OncLive® On Air

In today’s episode, we invited experts from across oncology specialties to discuss the abstracts and presentations they are most looking forward to seeing at the 2024 ESMO Congress. Emre Yekedüz, MD, an associate professor of medical oncology at Ankara University in Turkey and a research fellow at Dana-Farber Cancer Institute in Boston, Massachusetts, shared insights on his latest work in gastrointestinal malignancies, particularly in pancreatic and colorectal cancer. Thach-Giao Truong, MD, a hematologist and medical oncologist at the Cleveland Clinic in Ohio who specializes in skin cancers including basal cell carcinoma, melanoma, and Merkel cell carcinoma, highlighted her recent findings in targeted therapies for advanced skin cancers. John H. Strickler, MD, an associate professor of medicine in the Division of Medical Oncology at Duke University in Durham, North Carolina, emphasized key updates in the treatment of gastroesophageal malignancies, where he sees significant progress on the horizon. David Spigel, MD, chief scientific officer and medical oncologist at Sarah Cannon Research Institute in Nashville, Tennessee, discussed the expanding clinical trial program he oversees, ensuring patients have access to cutting-edge therapies. Finally, Paolo Tarantino, MD, a researcher at the European Institute of Oncology and clinical research fellow at Dana-Farber Cancer Institute, focused on advancements in breast cancer research, particularly in HER2-targeted therapies and antibody-drug conjugates.

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago. In this episode, OncLive On Air® partnered with Two Onc Docs to bring you a review session for the oncology board exams. Drs Armstrong and Tawagi discussed high-yield oncology and hematology topics to focus on during study sessions, memorization tricks they used for their own boards, and other tips for exam preparation.

In today’s episode, we had the pleasure of speaking with Narjust Florez, MD, about patient-focused lung cancer biomarker testing discussions.

Drs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.

Dr Salgia discusses how he chooses between tepotinib and capmatinib in patients with stage IV NSCLC harboring MET exon 14 skipping mutations.

Dr Chiang discusses the use of lurbinectedin in small cell lung cancer and tips for managing toxicities associated with this agent.

Dr Tewari discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

Dr Jhaveri discusses the INAVO120 trial of inavolisib plus palbociclib and fulvestrant in PIK3CA-mutant, HR-positive metastatic breast cancer.

Drs Park and Kasi delve into the shift toward neoadjuvant immunotherapy and the use of ctDNA as a prognostic tool in colorectal cancer.

Dr Garcia-Manero discusses findings from research in myelodysplastic syndromes that were presented at the 2024 EHA Congress.